Litcius/Paper detail

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Masoud Solaymani–Dodaran, Mostafa Ghanei, Mehdi Bagheri, Ali Qazvini, Ensieh Vahedi, Seyed Hassan Saadat, Seyed Amin Setarehdan, Akram Ansarifar, Hossein Biganeh, Arash Mohazzab, Davood Khalili, Amir Hosein Ghazale, Mohammad Heidari, Ali Taheri, Maliheh Khoramdad, Mohammad Mahdi Asadi, Masoud Nazemieh, Mojtaba Varshochi, Samaneh Abbasian, Ali Bakhtiari, Reza Mosaed, Seyyed‐Javad Hosseini‐Shokouh, Masoume Shahrokhi, Zeynab Yassin, Mohammad Ali Zohal, Maryam Qaraati, Nafiseh Rastgoo, Ramin Sami, Mohammad Eslami, Akram Asghari, Mansoor Namazi, Shadi Ziaie, Raana Jafari-Moghaddam, Saeid Kalantari, Mohammad Memarian, Javad Khodadadi, Mohammad Hossein Afshari, Mansooreh Momen–Heravi, Niusha Behzadseresht, Ahmad Reza Mobayen, Abolfazl Mozafari, Fatemeh Movasaghi, Maryam Haddadzadeh Shoushtari, Javad Moazen

2021International Immunopharmacology71 citationsDOIOpen Access PDF

Topics & Concepts

FavipiravirPneumoniaMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Betacoronavirus2019-20 coronavirus outbreakPandemicVirologyIntensive care medicineInternal medicineOutbreakDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia | Litcius